On 31 July, Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system disorders including Alzheimer's disease (AD) shared findings from its Phase IIb/III extension trial for blarcamesine at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto. The ATTENTION-AD open-label extension Phase IIb/III treatment trial followed an initial 48-week double-blind clinical trial for a total of up to 192 weeks (≈ 4 years). The trial was designed to evaluate the safety and tolerability of blarcamesine as well as its long-term effects on cognition (ADAS-Cog13) and function (ADCS-ADL) in people with early AD.
Participants treated with blarcamesine continue to show benefits through up to 4 years, as measured by the prespecified clinical endpoints ADAS-Cog13 and ADCS-ADL. In the intent-to-treat population, delayed-start analysis of treatment with oral blarcamesine was significant for both cognition and function. For ADAS-Cog13, results showed a significant difference between the early-start and late-start treatment groups at week 192. For ADCS-ADL, statistical significance was reached at week 192, also favouring the early-start group.